Pharmas

Source: uk.reuters.com --- 9 days ago
LONDON (Reuters) - The top share index was flat early on Wednesday as firmer metal and crude oil prices boosted commodity stocks, offsetting weakness in drugmakers. ...

Source: www.moreover.com --- 5 days ago
Therapeutics Daily Aug 30 2008 5:03PM GMT ...

Source: www.bignewsnetwork.com --- 18 days ago
0 posts The Royal Pharmaceutical Society of Great Britain is encouraging individual and team nominations for the Pharmas for Pharmacy Awards 2008, which are being held in Birmingham on 12 October. ... ...

Source: www.xconomy.com --- 19 hours ago
This week’s Boston-area life sciences news has a little bit of everything—venture deals, new drugs, lawsuits, and a big-time donation. And for the entrepreneurs among you looking for an alternative to the typical venture capital firm, check out Ryan’s directory of corporate VC operations. —The ranks of New England life sciences companies with their own venture [...] ...

Source: www.obbec.com --- 26 days ago
Big pharma companies, big lay-offs and big biotech deals. Stakeholders will be smiling as the pharma giants roll up their sleeves to set things right. While many consider the recent trend a knee-jerk reaction to declining profits and drug failures, people who pull the strings in these companies have a different view of the situation. Rising healthcare expenditures has been a major concern to the European governments. While price regulations and generic manufacturers are doing a great job in reducing the costs for the government, the companies developing drugs have not helped themselves. ...

Source: www.bloggingstocks.com --- 25 days ago
Filed under: Earnings reports , Pfizer (PFE) , Johnson and Johnson (JNJ) , Merck and Co (MRK) Johnson & Johnson (NYSE: JNJ ) shares rose over 2% by 12:45 on a day the market saw some scary dips earlier and the S&P 500 is still in the red. The health-care giant is rising after it reported its second-quarter financial results , posting an 8% growth in profit to $1.18 per share (excluding one time charges) and a 9% increase in total revenue to $16.45 billion. The results handily beat analyst expectations (according to Thomson Financial) of $1.12 per share, on revenue of $16 billion. Not only that, but the company also increased its 2008 earnings forecast. J&J execs claim the company wasn't being significantly hurt by the weakened U.S. economy, and judging from the effect of the lower dollar, which was responsible for 5.6% of the 9% higher revenue, perhaps they're right. Still, the company can't ignore that while international sales jumped 16.2% , U.S. sales increased only 2.1%. But among the different pharmaceutical companies, it seems there is little doubt that J&J is better poised to ride this global economic downturn; as opposed to to pure-play Pharmas, J&J has a more diversified business model. Already the difference was clear in this quarter's results and will probably make even more of a difference in the future, as many pharma companies lose sales to generic drug makers when products go off patent. This is the biggest challenge fa ...

Source: publicityhound.net --- 28 days ago
Leigh Ann Hubbard, managing editor of MyFamilyDoctorMag.com, writes: Periodically, in response to a request, I’ll get a quote from a doctor (via a publicist) that mentions a specific product. Inevitably, I Google the doctor and he or she has been or is on the payroll for the folks who make the product. There’s no mention of [...] ...

Source: online.wsj.com --- 57 days ago
Merck, Eli Lilly and Pfizer are forming a venture designed to create new drug-discovery methods and cut costs. ...

Source: seekingalpha.com --- 1 day ago
Ohad Hammer submits: The pharmaceutical industry is in the midst of a severe innovation crisis, where more R&D money results in less approved drugs. In parallel, sales of most traditional blockbusters are being cannibalized by generic competition, forcing the big Pharmas to exploit new concepts and rush new drug candidates to their pipelines. Nearly half of all drugs that are expected to enter the clinic in the coming years will be aimed at the oncology market. Consequently, early stage drug development for cancer is going to be the most active area in the industry, with an abundance of investment opportunities, particularly in small and medium companies. Complete Story » ...

Source: seekingalpha.com --- 25 days ago
ChinaBio Today submits: Last week, China biopharma saw news across a broad front. Earnings season is definitely underway, with three companies reporting, and there were developments in other areas – deals, drugs – as well. A significant venture capital funding was formally announced in China biopharma last week. HD Biosciences Inc., a Shanghai-based contract research organization [CRO], officially completed its Series A financing, after initially disclosing the fact at the ChinaBio Investor Forum held in early July (see story ). The round was led by Morningside Venture with Lilly Asian Ventures (NYSE: LLY) and Pfizer Venture Investments (NYSE: PFE) joining. The funding was especially significant because it may be the first time that multiple big Pharmas have taken an equity position in a China-based CRO. HD Biosciences is a specialized CRO focused on conducting assay development and high throughput screening services for big pharma and biotech. The funding will be used to expand HD Bioscience’s high throughput screening program and build new capabilities in in-vivo biology and DMPK bio-analytical services. Founded in 2002, HDB provides services to clients including 5 of the 10 world's largest multinational pharmaceutical companies. Complete Story » ...

Source: www.mmm-online.com --- 40 days ago
The Medicare prescription drug benefit has goosed pharma industry profits to the tune of $3.7 billion, said a report from Rep. Henry Waxman's Committee on Oversight and Government Reform. ...

Source: www.citywire.co.uk --- 63 days ago
The FTSE 100 had recovered most of its earlier losses by 1.09pm, thanks to a bounce among housebuilders, and a rally in Pharmas and selective banks to be trading down just four points at 5,426.70. ...

Source: www.inboxrobot.com --- 48 days ago
... Delhaize dented food retailers and producers. Delhaize lost 8.2 percent, while peers Ahold and Carrefour were down 3.5 percent and 0.2 percent respectively and Tesco fell 3.3 percent. L'Oreal fell 2.07 percent after issuing a warning on sales. Nestle ... ...

Source: www.indiaprwire.com --- 22 days ago
/India PRwire/ - Aris Global, world’s leading provider of software solutions for the global life sciences industry with a 600-member strong development centre in Bangalore , today announced that it has embarked on a strategic restructuring of its Global Products Delivery unit that will better support the company’s plans for aggressive growth in new products and services. Under the newly appointed leadership of Prashanth Visweswaran, Aris Global Vice President, Global Products Delivery (GPD), all functions specific to product delivery are now integrated as a single unit. Aris Global clientele include Indian and International players like Pfizer, Aurobindo, Daiichi- Sankyo, Dr. Reddy’s Laboratories, Johnson & Johnson, Lupin, Sanofi Aventis, Health Canada, Omnicare, etc. With more than 300 companies worldwide relying on their software, including 24 of the top 50 Pharmas, Aris Global helps life sciences organizations achieve success by helping them meet global regulatory obligations as also manage and help mitigate risks. It also helps improve operational efficiency and share information on a global basis and above all, lowers costs of managing R&D The new unit has also been reorganized with the appointment of a new high-caliber management team with diverse industry expertise and knowledge. This new management team will be responsible for realigning its Bangalore-based, 600-member delivery team to achieve higher efficiency levels and ...

Source: www.fiercehealthfinance.com --- 7 days ago
With healthcare facing some of its biggest financial challenges in years, particularly a growth in bad debt and slides in federal reimbursement, you wouldn't think that industry stocks would be doing too well. As usual, however, the market has followed its own logic, bringing several healthcare stocks to high points and pushing up the overall value Standard & Poor's healthcare stocks average by 4.4 percent (compared with a 7.9 percent drop in the overall index). Meanwhile, mutual funds focused on healthcare are up 6.84 percent over the past three months, according to Morningstar, the only category of stock funds in positive numbers during this period. Analysts say that rising healthcare stock performance is driven more by biotechs and Pharmas than provider companies. Their strong performance is partly due to improved performance by the stocks themselves, but also due to investors running away from finance and energy as well. Healthcare stocks have also been pushed up by foreign investors with strong currencies, who have been on the prowl to take over U.S. companies with below-expected valuations. Big gainers among the S&P 500 include generic drug-maker Barr, Amgen, Varian Medical Systems and King Pharmaceuticals. On the other hand, it's not all good news in this sector, as several managed care companies have lost value, including UnitedHealth Group and Aetna. (Aetna has lost value despite strong improvements in its fundamentals , ...

Source: www.fiercehealthcare.com --- 56 days ago
Taking control of what may have otherwise been forced upon it, the pharmaceutical industry has agreed to a voluntary code of conduct that bans gifts to physicians. The rules, the Code on Interactions with Health Care Professionals, was written by the Pharmaceutical Research and Manufacturers of America, the industry's trade organization. (If these power brokers have decided that it's time to give up the gifts, they must have been all but certain that private groups and legislatures were going to force an end to the practice.) The code includes a provision asking CEOs of the large pharmaceutical firms to certify in writing that they have policies and procedures in place that will encourage compliance with the new rules. All of this is well and good, from the standpoint of critics who'd like to see pharmaceutical companies step back from their physician relationships. However, they're still not completely happy, as the code still allows drugmakers to shower dollars with big-ticket consulting and speaking agreements and invite physicians to fancy dinners in the name of drug education. Also, the rules still allow Pharmas to set up breakfasts and lunches for medical office staffs. To learn more about the new rules: - read this article from The New York Times Related Articles: Congress debates pharma gift disclosure States tighten screws on pharma marketers NY bill would require Pharmas to report MD gifts Doctors weigh in on pros and c ...

Source: www.fiercehealthcare.com --- 51 days ago
> Pharmaceutical companies have been cutting sales forces recently. The most recent is Boehringer Ingelheim, which will halve the ranks of its neurology sales force. FiercePharma > The ongoing investigation of generic drug maker Ranbaxy now includes a look at charges that it made weak or impure HIV drugs given to thousands of African AIDS patients. FiercePharma > Researchers are working to develop a low-cost, next-gen pneumococcus vaccine that works against a wider range of pneumococcus bacteria than industry standard Prevnar. FierceVaccines > According to a new study by healthcare IT company Logicalis, data storage is the top driver behind many hospital IT projects underway right now. FierceHealthIT And Finally...  Nice try, lady. Just drop the rat and put your hands up. Article ...